The biology of a20-binding inhibitors of nf-kb activation (Abins)

Advances in Experimental Medicine and Biology

Volumn 809, Issue , 2014, Pages 13-31

  Verstrepen, Lynn ^a,b   Carpentier, Isabelle ^a,b   Beyaert, Rudi ^a,b  

^a GHENT UNIVERSITY   (Belgium)

^b DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

A20 BINDING INHIBITOR OF NUCLEAR FACTOR KAPPA B 1 PROTEIN; A20 BINDING INHIBITOR OF NUCLEAR FACTOR KAPPA B 2 PROTEIN; A20 BINDING INHIBITOR OF NUCLEAR FACTOR KAPPA B 3 PROTEIN; I KAPPA B; INTEGRASE; LIPOPOLYSACCHARIDE; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; A20 PROTEIN, MOUSE; DNA BINDING PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; SIGNAL PEPTIDE; SIGNAL TRANSDUCING ADAPTOR PROTEIN; UBIQUITIN PROTEIN LIGASE;

APOPTOSIS; BIOLOGICAL ACTIVITY; GENE REPLICATION; HUMAN; IMMUNE RESPONSE; LIVER INJURY; LIVER REGENERATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STRUCTURE; SEQUENCE HOMOLOGY; SIGNAL TRANSDUCTION; TUMOR GROWTH; UPREGULATION; AMINO ACID SEQUENCE; ANIMAL; CHEMISTRY; DRUG ANTAGONISM; METABOLISM; MOLECULAR GENETICS; MOUSE; REVIEW;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; AMINO ACID SEQUENCE; ANIMALS; DNA-BINDING PROTEINS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MICE; MOLECULAR SEQUENCE DATA; NF-KAPPA B; PROTEIN BINDING; SEQUENCE HOMOLOGY, AMINO ACID; UBIQUITIN-PROTEIN LIGASES;

EID: 84908032566     PISSN: 00652598     EISSN: 22148019     Source Type: Book Series    
DOI: 10.1007/978-1-4939-0398-6_2     Document Type: Chapter

References (86)

1. Karin M. The beginning of the end: IkappaB kinase (IKK) and NF-kappaB activation. J BioI Chern 1999; 274:27339-42; PMID: I 0488062; http://dx.doi.org/I 0.1 074/jbc.274.39.27339.
2. Gilmore TD. Introdnction to NF-kappaB: players, pathways, perspectives. Oncogene 2006; 25:6680-4; PMID: 17072321; http://dx.doi.org/I 0.1 038/sj.onc.1209954.
3. HotTmann A, Natoli G, Ghosh G. Transcriptional regulation via the NF-kappaB signaling module. Oncogene 2006; 25:6706-16; PMID: 17072323; http://dx.doi.orgIl0.1038/sj.onc.1209933.
4. Tak PP, Firestein GS. NF-kappaB: a key role in inflammatory diseases. J Clin Invest 2001; 107:7-11; PMID: 11134171; http://dx.doi.org/IO.1172/JCIlI830.
5. Perkins ND. Post-translational modifications regulating the activity and function ofthe nuclear factor kappa B pathway. Oncogene 2006; 25:6717-30; PMID: 17072324; http://dx.doi.org/IO.l038/sj.onc.1209937.
6. Karin M. The beginning of the end: IkappaB kinase (IKK) and NF-kappaB activation. J BioI Chern 1999; 274:27339-42; PMID: I 0488062; http://dx.doi.org/I 0.1 074/jbc.274.39.27339.
7. HeyninckK, De ValckD, Vanden Berghe W, Van Criekinge W, Contreras R, Fiers W, et al. The zinc finger protein A20 inhibits TNF-induced NF-kappaB-dependent gene expression by interfering with an RIP-or TRAF2-mediated transactivation signal and directly binds to a novel NF-kappaB-inhibiting protein ABIN. J Cell BioI 1999; 145:1471-82; PMID:I0385526; http://dx.doi.org/l0.1083/jcb.145.7.l471.
8. Karin M. The beginning of the end: IkappaB kinase (IKK) and NF-kappaB activation. J BioI Chern 1999; 274:27339-42; PMID: I 0488062; http://dx.doi.org/I 0.1 074/jbc.274.39.27339.
9. Karin M. The beginning of the end: IkappaB kinase (IKK) and NF-kappaB activation. J BioI Chern 1999; 274:27339-42; PMID: I 0488062; http://dx.doi.org/I 0.1 074/jbc.274.39.27339.
10. Karin M. The beginning of the end: IkappaB kinase (IKK) and NF-kappaB activation. J BioI Chern 1999; 274:27339-42; PMID: I 0488062; http://dx.doi.org/I 0.1 074/jbc.274.39.27339.
11. Karin M. The beginning of the end: IkappaB kinase (IKK) and NF-kappaB activation. J BioI Chern 1999; 274:27339-42; PMID: I 0488062; http://dx.doi.org/I 0.1 074/jbc.274.39.27339.
12. Karin M. The beginning of the end: IkappaB kinase (IKK) and NF-kappaB activation. J BioI Chern 1999; 274:27339-42; PMID: I 0488062; http://dx.doi.org/I 0.1 074/jbc.274.39.27339.
13. Karin M. The beginning of the end: IkappaB kinase (IKK) and NF-kappaB activation. J BioI Chern 1999; 274:27339-42; PMID: I 0488062; http://dx.doi.org/I 0.1 074/jbc.274.39.27339.
14. Tian B, NowakDE, JamaluddinM, Wang S, Brasier AR. Identification of direct genomic targets downstream of the nuclear factor-kappaB transcription factor mediating tumor necrosis factor signaling. J Bioi Chern 2005; 280:17435-48; PMID: 15722553; http://dx.doi.orgIl0.1074/jbc.M500437200.
15. Hinata K, Gervin AM, Jennifer Zhang Y, Khavari PA. Divergent gene regulation and growth effects by NF-kappa B in epithelial and mesenchymal cells of human skin. Oncogene 2003; 22:1955-64; PMID: 1267320 1; http://dx.doi.orgll 0.1038/sj.onc.1206198.
16. GallagherJ, HowlinJ,McCarthyC, MurphyEP, Bresnihan B, FitzGeral dO, etal. IdentificationotNafl/ABIN-1 among TNF-alpha-induced expressed genes in human synoviocytes using oligonucleotide microarrays. FEBS Lett 2003; 551:8-12; PMID: 12965196; http://dx.doi.org/IO.1016/S0014-5793(03)00823-8.
17. Karin M. The beginning of the end: IkappaB kinase (IKK) and NF-kappaB activation. J BioI Chern 1999; 274:27339-42; PMID: I 0488062; http://dx.doi.org/I 0.1 074/jbc.274.39.27339.
18. Viemann D, Goebeler M, Schmid S, Klimmek K, Sorg C, Ludwig S, et al. Transcriptional profiling of IKK2INF-kappa B-and p38 MAP kinase-dependent gene expression in TNF-alpha-stimulated primary human endothelial cells. Blood 2004; 103:3365-73; PMID: 14715628; http://dx.doi.orgIl0.1182/blood-2003-09-3296.
19. Nemeth ZH, Leibovich SJ, Deitch EA, Vizi ES, Szab C, Hasko G. eDNA microarray analysis reveals a nuclear factor-kappaB-independent regulation of macrophage function by adenosine. J Pharmacol Exp Ther 2003; 306:1042-9; PMID: 12766259; http://dx.doi.org/10.1124/jpet.l03.052944.
20. Hinz M, Lemke P, Anagnostopoulos I, Hacker C, Krappmann D, Mathas S, et al. Nuclear factor kappaB-dependent gene expression profiling of Hodgkin ' s disease tumor cells, pathogenetic signiticance, and link to constitutive signal transducer and activator of transcription 5a activity. J Exp Med 2002; 196:605-17; PMID: 12208876; http://dx.doi.orgll 0.1 084/jem.20020062.
21. Karin M. The beginning of the end: IkappaB kinase (IKK) and NF-kappaB activation. J BioI Chern 1999; 274:27339-42; PMID: I 0488062; http://dx.doi.org/I 0.1 074/jbc.274.39.27339.
22. Karin M. The beginning of the end: IkappaB kinase (IKK) and NF-kappaB activation. J BioI Chern 1999; 274:27339-42; PMID: I 0488062; http://dx.doi.org/I 0.1 074/jbc.274.39.27339.
23. Bi Y, Zeng N, Chanudet E, Huang Y, Hamoudi RA, Liu H, et al. A20 inactivation in ocular adnexal MALT lymphoma. Haematologica 2012; 97:926-30; http://dx.doi.orgIl0.3324/haemato!'2010.036798.
24. Huang L, Verstrepen L, Heyninck K, Wullaert A, Revets H, De Baetselier P, et al. ABINs inhibit EGF receptor-mediated NF-kappaB activation and growth of EGF receptor-overexpressing tumour cells. Oncogene 2008; 27:6131-40; PMlD: 18622428; http://dx.doi.org/IO.l038/onc.2008.208.
25. Karin M. The beginning of the end: IkappaB kinase (IKK) and NF-kappaB activation. J BioI Chern 1999; 274:27339-42; PMID: I 0488062; http://dx.doi.org/I 0.1 074/jbc.274.39.27339.
26. Mauro C, Pacifico F, Lavorgna A, Mellone S, Iannetti A, Acquaviva R, et al. ABTN-I binds to NEMO/ IKKgamma and co-operates with A20 in inhibiting NF-kappaB. J BioI Chern 2006; 281:18482-8; PMlD: 16684768; http://dx.doi.org/l 0.1 074/jbc.M60 1502200.
27. Karin M. The beginning of the end: IkappaB kinase (IKK) and NF-kappaB activation. J BioI Chern 1999; 274:27339-42; PMID: I 0488062; http://dx.doi.org/I 0.1 074/jbc.274.39.27339.
28. Wagner S, Carpentier I, Rogov V, Kreike M, Ikeda F, Uihr F, et al. Ubiquitin binding mediates the NF-kappaB inhibitory potential of ABIN proteins. Oncogene 2008; 27:3739-45; PMlD: 18212736; http://dx.doi.org/IO.1038/sj.onc.1211042.
29. Ea CK, Deng L, Xia ZP, Pineda G, Chen ZJ. Activation of IKK by TNFalpha requires site-specific ubiquitination of RIP 1 and polyubiquitin binding byNEMO. Mol Cell 2006; 22:245-57; PMTD:16603398; http://dx.doi.org/I 0.1 0 16/j.molceI.2006.03.026.
30. Karin M. The beginning of the end: IkappaB kinase (IKK) and NF-kappaB activation. J BioI Chern 1999; 274:27339-42; PMID: I 0488062; http://dx.doi.org/I 0.1 074/jbc.274.39.27339.
31. Karin M. The beginning of the end: IkappaB kinase (IKK) and NF-kappaB activation. J BioI Chern 1999; 274:27339-42; PMID: I 0488062; http://dx.doi.org/I 0.1 074/jbc.274.39.27339.
32. Karin M. The beginning of the end: IkappaB kinase (IKK) and NF-kappaB activation. J BioI Chern 1999; 274:27339-42; PMID: I 0488062; http://dx.doi.org/I 0.1 074/jbc.274.39.27339.
33. Karin M. The beginning of the end: IkappaB kinase (IKK) and NF-kappaB activation. J BioI Chern 1999; 274:27339-42; PMID: I 0488062; http://dx.doi.org/I 0.1 074/jbc.274.39.27339.
34. Bouwmeester T, Bauch A, Ruffner H, Angrand PO, Bergamini G, Croughton K, et al. A physical and functional map of the human TNF-alpha/NF-kappa B signal transduction pathway. Nat Cell BioI 2004; 6:97-105; PMTD: 14743216; http://dx.doi.org/l0.l038/ncbl086.
35. Karin M. The beginning of the end: IkappaB kinase (IKK) and NF-kappaB activation. J BioI Chern 1999; 274:27339-42; PMID: I 0488062; http://dx.doi.org/I 0.1 074/jbc.274.39.27339.
36. Karin M. The beginning of the end: IkappaB kinase (IKK) and NF-kappaB activation. J BioI Chern 1999; 274:27339-42; PMID: I 0488062; http://dx.doi.org/I 0.1 074/jbc.274.39.27339.
37. Karin M. The beginning of the end: IkappaB kinase (IKK) and NF-kappaB activation. J BioI Chern 1999; 274:27339-42; PMID: I 0488062; http://dx.doi.org/I 0.1 074/jbc.274.39.27339.
38. Karin M. The beginning of the end: IkappaB kinase (IKK) and NF-kappaB activation. J BioI Chern 1999; 274:27339-42; PMID: I 0488062; http://dx.doi.org/I 0.1 074/jbc.274.39.27339.
39. Karin M. The beginning of the end: IkappaB kinase (IKK) and NF-kappaB activation. J BioI Chern 1999; 274:27339-42; PMID: I 0488062; http://dx.doi.org/I 0.1 074/jbc.274.39.27339.
40. Karin M. The beginning of the end: IkappaB kinase (IKK) and NF-kappaB activation. J BioI Chern 1999; 274:27339-42; PMID: I 0488062; http://dx.doi.org/I 0.1 074/jbc.274.39.27339.
41. El Bakkouri K, Wullaert A, Haegman M, Heyninck K, Beyaert R. Adenoviral gene transfer ofthe NF-kappa B inhibitory protein ABIN-I decreases allergic airway inflammation in a murine asthma model. J Bioi Chern 2005; 280: 17938-44; PMTD: 15722346; http://dx.doi.org/l0.l074/jbc.M413588200.
42. Wullaert A, Wielockx B, Van Huffel S, Bogaert V, De Geest B, Papeleu P, et a!. Adenoviral gene transfer of ABIN-l protects mice from TNF/galactosamine-induced acute liver failure and lethality. Hepatology 2005; 42:381-9; PMTD:16025521; http://dx.doi.orgl I0.l 002/hep.20785.
43. Gonzalez-Amaro R, Garcia-Monzon C, Garcia-Buey L, Moreno-Otero R, Alonso JL, Yaglie E, et al. Induction of tumor necrosis factor alpha production by human hepatocytes in chronic viral hepatitis. J Exp Med 1994; 179:841-8; PMID:7509363; http://dx.doi.orgl I0.l 084/j em.179.3.841.
44. Karin M. The beginning of the end: IkappaB kinase (IKK) and NF-kappaB activation. J BioI Chern 1999; 274:27339-42; PMID: I 0488062; http://dx.doi.org/I 0.1 074/jbc.274.39.27339.
45. Karin M. The beginning of the end: IkappaB kinase (IKK) and NF-kappaB activation. J BioI Chern 1999; 274:27339-42; PMID: I 0488062; http://dx.doi.org/I 0.1 074/jbc.274.39.27339.
46. Karin M. The beginning of the end: IkappaB kinase (IKK) and NF-kappaB activation. J BioI Chern 1999; 274:27339-42; PMID: I 0488062; http://dx.doi.org/I 0.1 074/jbc.274.39.27339.
47. Karin M. The beginning of the end: IkappaB kinase (IKK) and NF-kappaB activation. J BioI Chern 1999; 274:27339-42; PMID: I 0488062; http://dx.doi.org/I 0.1 074/jbc.274.39.27339.
48. Karin M. The beginning of the end: IkappaB kinase (IKK) and NF-kappaB activation. J BioI Chern 1999; 274:27339-42; PMID: I 0488062; http://dx.doi.org/I 0.1 074/jbc.274.39.27339.
49. Karin M. The beginning of the end: IkappaB kinase (IKK) and NF-kappaB activation. J BioI Chern 1999; 274:27339-42; PMID: I 0488062; http://dx.doi.org/I 0.1 074/jbc.274.39.27339.
50. Karin M. The beginning of the end: IkappaB kinase (IKK) and NF-kappaB activation. J BioI Chern 1999; 274:27339-42; PMID: I 0488062; http://dx.doi.org/I 0.1 074/jbc.274.39.27339.
51. Nair RP, Duffin KC, Helms C, Ding J, Stuart PE, Goldgar D, et al.; Collaborative Association Study of Psoriasis. Genome-wide scan reveals association of psoriasis with IL-23 and NF-kappaB pathways. Nat Genet 2009; 41: 199-204; PMID: 19169254; http://dx.doi.org/1O.1038/ng.311.
52. Han JW, Zheng HF, Cui Y, Sun LD, Ye DQ, Hu Z, et a!. Genome-wide association study in a Chinese Han population identifies nine new susceptibility loci for systemic lupus erythematosus. Nat Genet 2009; 41: 1234-7; PMID: 19838193; http://dx.doi.org/1O.l038/ng.472.
53. Karin M. The beginning of the end: IkappaB kinase (IKK) and NF-kappaB activation. J BioI Chern 1999; 274:27339-42; PMID: I 0488062; http://dx.doi.org/I 0.1 074/jbc.274.39.27339.
54. Karin M. The beginning of the end: IkappaB kinase (IKK) and NF-kappaB activation. J BioI Chern 1999; 274:27339-42; PMID: I 0488062; http://dx.doi.org/I 0.1 074/jbc.274.39.27339.
55. Igarashi H, Yahagi A, Saika T, Hashimoto J, Tomita T, Yoshikawa H, et al. A pro-inflammatory role for A20 and ABTN family proteins in human fibroblast-like synoviocytes in rheumatoid arthritis. Immunol Lett 2012; 141:246-53; PMTD:22093807; http://dx.doi.org/l 0.l 016/j.i ml et.2011.1 0.011.
56. Karin M. The beginning of the end: IkappaB kinase (IKK) and NF-kappaB activation. J BioI Chern 1999; 274:27339-42; PMID: I 0488062; http://dx.doi.org/I 0.1 074/jbc.274.39.27339.
57. Karin M. The beginning of the end: IkappaB kinase (IKK) and NF-kappaB activation. J BioI Chern 1999; 274:27339-42; PMID: I 0488062; http://dx.doi.org/I 0.1 074/jbc.274.39.27339.
58. Hughes DP, Marron MB, Brindle NP. The antiinflammatory endothelial tyrosine kinase Tie2 interacts with a novel nuclear factor-kappaB inhibitor ABTN-2. Circ Res 2003; 92:630-6; PMTD: 12609966; http://dx.doi.orgll0.1161/01.RES.0000063422.38690.DC.
59. Li CC, Chou CK, Wang MH, Tsai TF. Overexpression of ABTN-2, a negative regulator ofNF-kappaB, delays liver regeneration in theABIN-2 transgenic mice. Biochem Biophys Res Commun 2006; 342:300-9; PMTD: 16480954; http://dx.doi.org/l 0.l 016/j.bbrc.2006.01.114.
60. Karin M. The beginning of the end: IkappaB kinase (IKK) and NF-kappaB activation. J BioI Chern 1999; 274:27339-42; PMID: I 0488062; http://dx.doi.org/I 0.1 074/jbc.274.39.27339.
61. Brewer G. An A + U-rich element RNA-binding factor regulates c-myc mRNA stability in vitro. Mol Cell BioI 1991; 11:2460-6; PMID:1901943.
62. Karin M. The beginning of the end: IkappaB kinase (IKK) and NF-kappaB activation. J BioI Chern 1999; 274:27339-42; PMID: I 0488062; http://dx.doi.org/I 0.1 074/jbc.274.39.27339.
63. Karin M. The beginning of the end: IkappaB kinase (IKK) and NF-kappaB activation. J BioI Chern 1999; 274:27339-42; PMID: I 0488062; http://dx.doi.org/I 0.1 074/jbc.274.39.27339.
64. Ye J, Xie X, Tarassishin L, Horwitz MS. Regulation of the NF-kappaB activation pathway by isolated domains of FIP3!1KKgamma, a component of the IkappaB-alpha kinase complex. J BioI Chern 2000; 275:9882-9; PMlD: 10734145; http://dx.doi.org/l 0.1 074/jbc.275.13. 9882.
65. Karin M. The beginning of the end: IkappaB kinase (IKK) and NF-kappaB activation. J BioI Chern 1999; 274:27339-42; PMID: I 0488062; http://dx.doi.org/I 0.1 074/jbc.274.39.27339.
66. Karin M. The beginning of the end: IkappaB kinase (IKK) and NF-kappaB activation. J BioI Chern 1999; 274:27339-42; PMID: I 0488062; http://dx.doi.org/I 0.1 074/jbc.274.39.27339.
67. Hermoso MA, Cidlowski JA. Putting the brake on inflammatory responses: the role of glucocorticoids. IUBMB Life 2003; 55:497-504; PMID:14658755; http://dx.doi.org/l0.l080/15216540310001642072.
68. Karin M. The beginning of the end: IkappaB kinase (IKK) and NF-kappaB activation. J BioI Chern 1999; 274:27339-42; PMID: I 0488062; http://dx.doi.org/I 0.1 074/jbc.274.39.27339.
69. Karin M. The beginning of the end: IkappaB kinase (IKK) and NF-kappaB activation. J BioI Chern 1999; 274:27339-42; PMID: I 0488062; http://dx.doi.org/I 0.1 074/jbc.274.39.27339.
70. Kim I, Kim HG, So IN, Kim JH, Kwak HJ, Koh GY. Angiopoietin-l regulates endothelial cell survival through the phosphatidylinositol 3'-Kinase/Akt signal transduction pathway. Circ Res 2000; 86:24-9; PMID: 1062530 1; http://dx.doi.org/l 0.116110 I.RES.86.1.24.
71. Karin M. The beginning of the end: IkappaB kinase (IKK) and NF-kappaB activation. J BioI Chern 1999; 274:27339-42; PMID: I 0488062; http://dx.doi.org/I 0.1 074/jbc.274.39.27339.
72. Karin M. The beginning of the end: IkappaB kinase (IKK) and NF-kappaB activation. J BioI Chern 1999; 274:27339-42; PMID: I 0488062; http://dx.doi.org/I 0.1 074/jbc.274.39.27339.
73. Kim I, Moon SO, Park SK, Chae SW, Koh GY. Angiopoietin-l reduces VEGF-stimulated leukocyte adhesion to endothelial cells by reducing rCAM-l, VCAM-l, and E-selectin expression. Circ Res 2001; 89:477-9; PMTD:11557733; http://dx.doi.org/10.1161/hh 1801.097034.
74. Karin M. The beginning of the end: IkappaB kinase (IKK) and NF-kappaB activation. J BioI Chern 1999; 274:27339-42; PMID: I 0488062; http://dx.doi.org/I 0.1 074/jbc.274.39.27339.
75. Tadros A, Hughes DP, Dunmore BJ, Brindle NP. ABTN-2 protects endothelial cells from death and has a role in the antiapoptotic effect of angiopoietin-l. Blood 2003; 102:4407-9; PMlD:12933576; http://dx.doi.org/l0.1182/blood-2003-05-1602.
76. Lang V, Symons A, Watton SJ, Janzen J, Soneji Y, Beinke S, et al. ABTN-2 forms a ternary complex with TPL-2 andNF-kappa Bl pI 05 and is essential for TPL-2 protein stability. Mol Cell BioI 2004; 24:5235-48.
77. Karin M. The beginning of the end: IkappaB kinase (IKK) and NF-kappaB activation. J BioI Chern 1999; 274:27339-42; PMID: I 0488062; http://dx.doi.org/I 0.1 074/jbc.274.39.27339.
78. Karin M. The beginning of the end: IkappaB kinase (IKK) and NF-kappaB activation. J BioI Chern 1999; 274:27339-42; PMID: I 0488062; http://dx.doi.org/I 0.1 074/jbc.274.39.27339.
79. Karin M. The beginning of the end: IkappaB kinase (IKK) and NF-kappaB activation. J BioI Chern 1999; 274:27339-42; PMID: I 0488062; http://dx.doi.org/I 0.1 074/jbc.274.39.27339.
80. Karin M. The beginning of the end: IkappaB kinase (IKK) and NF-kappaB activation. J BioI Chern 1999; 274:27339-42; PMID: I 0488062; http://dx.doi.org/I 0.1 074/jbc.274.39.27339.
81. Jenne DE, Reimann H, Nezu J, Friedel W, LotT S, Jeschke R, et al. Peutz-Jeghers syndrome is caused by mutations in a novel serine threonine kinase. Nat Genet 1998; 18:38-43; PMTD:9425897; http://dx.doi. orgll 0.1 038/ngO 198-38.
82. Staege H, Brauchlin A, Schoedon G, Schaffuer A. Two novel genes FIND and LIND differentially expressed in deactivated and Listeria-infected human macrophages. Immunogenetics 2001; 53: I 05-13; PMlD: 11345586; http://dx.doi.org/l 0.1 007/s00251O 100306.
83. Weaver BK, Bohn E, Judd BA, Gil MP, Schreiber RD. ABTN-3: a molecular basis for species divergence in interleukin-I O-induced anti-inflammatory actions. Mol Cell BioI 2007; 27:4603-16; PMlD: 17485448; http://dx.doi.orgI10.1128IMCB.00223-07.
84. Karin M. The beginning of the end: IkappaB kinase (IKK) and NF-kappaB activation. J BioI Chern 1999; 274:27339-42; PMID: I 0488062; http://dx.doi.org/I 0.1 074/jbc.274.39.27339.
85. Sakai Y, Uchida K, Nakayama H. A20 and ABIN-3 possibly promote regression oftrehalose 6,6'-dimycolate (TDM)-induced granuloma by interacting with an NF-kappa B signaling protein, TAK-l. Inflamm Res 2012; 61:245-53; PMlD:22173278; http://dx.doi.org/10.1007/s00011-011-0406-6.
86. Wang L, Gordon RA, Huynh L, Su X, Park Min KH, Han J, et at. Indirect inhibition of Toll-like receptor and type I interferon responses by lTAM-coupled receptors and integrins. Immunity 2010; 32:518-30; PMlD:20362473; http://dx.doi.orgl l 0.l 016/j.i mmuni.2010.03.014.